---
title: "Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295097103.md"
description: "Xeris Biopharma reported Q2 FY26 revenue of $92.1 million, up 29% year-over-year, driven by an 81% surge in Recorlev sales to $57 million. However, GAAP net loss widened to $31.1 million due to a $31 million non-cash charge related to convertible note exchanges. Gross margin improved to 86%. The company tightened its full-year 2026 revenue guidance to $385-$390 million and noted Keveyis patent protection extends through at least 2039."
datetime: "2026-08-06T11:14:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295097103.md)
  - [en](https://longbridge.com/en/news/295097103.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295097103.md)
generator: "portal-rs"
---

# Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 million

-   Xeris Biopharma Q2 2026 revenue rose 29% year over year to $92.1 million; net product revenue climbed 34% to $91 million. \* GAAP net loss widened to $31.1 million, due to a one-time, non-cash charge of about $31 million tied to 2028 Convertible Notes exchanges. \* GAAP gross margin improved 4 percentage points to 86%. \* Recorlev net revenue more than doubled, up 81% year over year to about $57 million. \* Tightened full-year 2026 revenue guidance to $385 million-$390 million; Keveyis patent allowance expected to extend protection through at least 2039. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [XERS.US](https://longbridge.com/en/quote/XERS.US.md)

## Related News & Research

- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [GE HealthCare declares Q3 2026 distribution of R$ 0.02 per unit](https://longbridge.com/en/news/296242723.md)
- [HAV Group schedules Q2 2026 results webcast presentation](https://longbridge.com/en/news/296448086.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**